Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This clinical trial was designed to investigate the efficiency and toxicity of fractionated
stereotactic radiotherapy(FSRT) combined with Temozolomide(TMZ) for refractory brain
metastases.